Company Overview
| Stock Name | Austar |
|---|---|
| Stock Code | 06118 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家在中國領先的高端綜合服務及產品一體化工程解決方案供應商,面向在中國的知名製藥企業及研究機構,亦在新興國家向客戶提供此等服務和產品。解決方案涵蓋流體與生物工藝系統、潔淨室及自動化控制與監控系統、粉體固體系統及GMP合規性服務,並從事高端製藥設備及生命科技耗材的製造、銷售及分銷。 |
| Listing Date | 2014-11-07 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 北京市朝陽區朝外大街26號朝外門寫字中心B座1801室 |
| Business Address (Hong Kong) | 香港新界沙田安平街6號新貿中心1樓6室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.austar.com.hk |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 3.12 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2014-10-28 to 2014-10-31 |
| Global Offering Shares | 125,000,000 shares |
| HK Public Offer Shares (Initial) | 12,500,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 112,500,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 500,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 390,000,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 359.8M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +2600% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣53.6百萬元 |
| Period-End Cash Balance | 人民幣139.7百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2011 | 2012 | 2013 | 2014-06 |
|---|---|---|---|---|
| Revenue | 325,178 | 420,753 | 705,153 | 320,823 |
| Cost of sales | -224,657 | -284,304 | -490,187 | -207,086 |
| Gross profit | 100,521 | 136,449 | 214,966 | 113,737 |
| Other income and gains, net | 305 | 418 | 1,130 | 590 |
| Selling and distribution expenses | -28,528 | -36,760 | -72,104 | -32,374 |
| Administrative expenses | -24,502 | -35,383 | -47,849 | -30,568 |
| Operating profit | 36,451 | 48,485 | 72,200 | 40,572 |
| Net finance costs | -684 | -1,301 | -42 | 303 |
| Share of associates and JVs | 2,631 | 4,102 | 4,495 | 2,579 |
| Profit before tax | 38,398 | 51,286 | 76,653 | 43,454 |
| Income tax expense | -11,061 | -15,777 | -23,082 | -10,705 |
| Profit for the year | 27,337 | 35,509 | 53,571 | 32,749 |
| Profit attributable to owners | 27,258 | 35,476 | 53,571 | 32,750 |
Balance Sheet
| Item | 2011 | 2012 | 2013 | 2014-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 37,499 | 102,611 | 139,712 | 52,346 |
| Trade and bills receivables | 122,348 | 174,618 | 201,507 | 241,557 |
| Inventories | 54,586 | 49,008 | 74,550 | 65,197 |
| Total current assets | 250,596 | 377,853 | 537,474 | 481,313 |
| Total assets | 299,893 | 437,053 | 606,853 | 555,707 |
| Total current liabilities | 238,878 | 357,446 | 466,199 | 337,362 |
| Total liabilities | 242,623 | 364,464 | 478,478 | 349,070 |
| Total equity | 57,270 | 72,589 | 128,375 | 206,637 |
| Equity attributable to owners | 56,976 | 72,587 | 128,374 | 206,636 |
| Interest-bearing borrowings | 24,000 | 24,000 | 20,000 | 35,000 |
Cash Flow Statement
| Item | 2011 | 2012 | 2013 | 2014-06 |
|---|---|---|---|---|
| Net cash from operating activities | 16,918 | 73,981 | 71,407 | -84,571 |
| Net cash from investing activities | -7,165 | -24,759 | -44,549 | 17,589 |
| Net cash from financing activities | 5,148 | 16,886 | 10,254 | -20,373 |
| Net increase in cash | 14,901 | 66,108 | 37,112 | -87,355 |
| Purchase of PP&E | -6,548 | -5,950 | -11,049 | -7,159 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 3.57 |
|---|---|
| First Day Open | HK$ 3.85 |
| First Day Change | 14.42% |
| First Day Volume | 130979000.0 |
| First Day Turnover | 489046000.0 |
| Use of Proceeds | 1、約39.6%或134.4百萬港元將用于成立石家莊研發與制造中心,其中:
1.1 約9.2%或31.1百萬港元將用于收購土地;
1.2 約20.4%或69.3百萬港元將用于為生產設施的開發及建設成本提供資金;
1.3 約9.1%或30.8百萬港元將用于為粉體固體系統應用中心以及流體工藝應用中心的開發及建設成本以及設備采購成本提供資金;
1.4 約0.9%或3.1百萬港元將用于為生產廠房購買設備。
2、約14.2%或48.2百萬港元將用于為松江制造中心的開發提供資金,其中:
2.1約13.8%或46.7百萬港元將用于為生產設施的建設提供資金;
2.2約0.4%或1.5百萬港元將用于購買設備。
3、約6.8%或23.1百萬港元將用于通過為銷售及市場推廣團隊聘用額外雇員、為加強市場滲透成立額外代表辦事處及開展市場推廣活動(如組織及出席研討會、展覽會及會議)擴展銷售及市場推廣網絡;
4、約9.5%或32.1百萬港元將用于為研發活動提供資金,包括增加研發團隊人員數目的成本及研發項目投資;
5、約20.0%或67.9百萬港元將用于收購我們未來可能于中國、北美或歐洲物色的于制藥設備、工藝系統及服務市場擁有關鍵產品技術的公司之權益;
6、約9.9%或33.7百萬港元將用作營運資金及其他一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
海通国际资本有限公司 CE ADQ859
Overall Coordinators (1)
海通国际证券有限公司 CE AAF806
Joint Lead Managers (3)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 何國強 | — |
| Company Secretary | 陳煒聰 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 何國強先生(通過SFH)持有66.75%,顧女士(通過HCV)持有0.75%,合共67.50%;何建紅先生(通過TWG)持有7.50%。 |
|---|




